Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.67 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970830 | 0.81 | NR3C1 (0.62) | NR3C1LMNAMAPT | |
| SCHEMBL3969779 | 0.81 | NR3C1 (1.00) | NR3C1PGRNR3C2AR | |
| SCHEMBL3963496 | 0.77 | NR3C1 (0.57) | NR3C1PGRNR3C2ARMAPT | |
| SCHEMBL3965397 | 0.77 | NR3C1 (0.90) | NR3C1PGRNR3C2AR | |
| SCHEMBL649142 | 0.76 | RAB9A (0.57) | NR3C1CA1CA2LMNAMAPT | |
| SCHEMBL15392053 | 0.75 | MAPT (0.61) | NR3C1LOXL2CA1CA2MAPT | |
| SCHEMBL10397250 | 0.75 | MAPT (0.61) | NR3C1LOXL2CA1CA2MAPT | |
| Hydrochloric Acid SCHEMBL16699846 | 0.74 | MAPT (0.60) | NR3C1LOXL2CA1CA2MAPT | |
| SCHEMBL13052122 | 0.74 | ACHE (0.66) | LOXL2CA1CA2LMNAMAPT | |
| SCHEMBL12880407 | 0.73 | CA1 (0.56) | NR3C1LOXL2CA1CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363876-B1 | GLUCOCORTICOID RECEPTOR MODULATORS | KAROBIO AB (SE) | 2009-07-29 | — | — | EP | disclosed |
| US-6583180-B2 | Antidiabetic agents | ABBOTT LABORATORIES | 2003-06-24 | — | — | US | disclosed |
| US-20020156311-A1 | Glucocorticoid receptor modulators | KARO BIO AB (SE) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156311-A1 | Glucocorticoid receptor modulators | NR3C1, NR5A1, NR3C2 | NR3C1 1/4885LOXL2 3624/4885PGR 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.